Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
ApexOnco Front Page
Recent articles
Pivotal data set the stage for slightly delayed US accelerated approval filing.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The players are vying in the CD19 x CD20 Car-T arena.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
But the former is paying a fraction of what Merck shelled out for raludotatug.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
